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Background
East London has a diverse population profile, where many
of the inhabitants come from abroad. Consequently, they
harbour viruses from the farthest corners of the globe,
which partly reflect the worldwide HIV-1 epidemic. We
have looked at antibody responses in this cohort and tried
to establish the relationship of neutralising antibodies to
viruses from the same versus different clades.
Methods
To date, >330 patients have been recruited. Neutralisation
activity in plasma extracted from the treatment-naive
patients was determined on TzmBl cells with a panel of 11
viruses, representing 6 different clades.
Results
Overall, the plasmas do not differ much between the
groups in terms of virus neutralisation. However, we did
find that clade C infected individuals neutralised the
tested clade C viruses significantly better than the clade B
patients. Moreover, following titrations clade C plasmas
neutralised a CRF02_AG virus better than the AG samples.
Conclusion
Neutralisation activities appeared relatively sporadic and
independent of genetic clades, although we suggest that
clade C exposure may induce a neutralising humoral
response to help control clade C and CRF02_AG chal-
lenge.
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